Davenport Group | Functional Genomics

Davenport Group | Functional Genomics

Davenport Group

Our Research and Approach

Functional Genomics of Disease Response Heterogeneity
Emma Davenport will be leading a Faculty research group the Wellcome Sanger Institute in October 2018
Emma Davenport will be leading a Faculty research group the Wellcome Sanger Institute in October 2018

Starting in October 2018 the research team will be led by Emma Davenport from Harvard Medical Schools, Brigham and Women's Hospital and the Broad Institute. The group's research interests will lie in combining genomic analysis with clinical data to understand the underlying genetic reasons why some patients are able to overcome infections more quickly than others and why people respond differently to the same drug.

The team will focus on discovering the differences in our genomes that determine how active our genes are and how they affect how our bodies respond to particular drug treatments. The researchers will use both computational approaches and wet laboratory experiments to identify the areas of the genome that play a role in a disease by lowering or raising the activity of specific genes, discover which biological processes are involved, in which cells and when. This work will help to identify new drug targets and biomarkers that could be used in diagnostic tests.

The work will also show how a person’s genetic makeup interacts with drugs to enable or inhibit their effectiveness. Some drugs work better when certain genes are more or less active. While other drugs have their effect by working directly on the DNA regions that control a gene’s activity, either driving its activity up to supply unmet need, or reducing its activity to remove damaging excess.

About Emma Davenport

Emma's research interests lie in applying sophisticated analytical strategies to cohorts of patients to improve the treatment of disease. She focuses on integrating functional genomics and clinical data in order to understand how genetics contributes to the patient-to-patient heterogeneity in treatment response. Emma completed her PhD research in 2014 under the supervision of Professor Julian Knight at the University of Oxford. In 2015, she joined Professor Soumya Raychaudhuri's lab at Harvard Medical School as a postdoctoral research fellow. Her PhD and postdoctoral research have given her a strong foundation in computational methods, wet lab molecular biology and data acquisition.


Research Programmes and Faciltites


  • Discovering in vivo cytokine eQTL interactions from a lupus clinical trial

    Emma Elisabeth Davenport, Tiffany Amariuta, Maria Gutierrez-Arcelus, Kamil Slowikowski, Harm-Jan Westra et al.

    bioRxiv 2018

  • A community approach to mortality prediction in sepsis via gene expression analysis.

    Sweeney TE, Perumal TM, Henao R, Nichols M, Howrylak JA et al.

    Nature communications 2018;9;1;694

  • Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study.

    Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE et al.

    The Lancet. Respiratory medicine 2017;5;10;816-826

  • Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia.

    Burnham KL, Davenport EE, Radhakrishnan J, Humburg P, Gordon AC et al.

    American journal of respiratory and critical care medicine 2017;196;3;328-339

  • Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.

    Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P et al.

    The Lancet. Respiratory medicine 2016;4;4;259-71

  • Chronic mucocutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility.

    Dhalla F, Fox H, Davenport EE, Sadler R, Anzilotti C et al.

    Clinical and experimental immunology 2016;184;2;216-27

  • Application of whole genome and RNA sequencing to investigate the genomic landscape of common variable immunodeficiency disorders.

    van Schouwenburg PA, Davenport EE, Kienzler AK, Marwah I, Wright B et al.

    Clinical immunology (Orlando, Fla.) 2015;160;2;301-14

  • Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.

    Taylor JC, Martin HC, Lise S, Broxholme J, Cazier JB et al.

    Nature genetics 2015;47;7;717-726

  • Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study.

    Rautanen A, Mills TC, Gordon AC, Hutton P, Steffens M et al.

    The Lancet. Respiratory medicine 2015;3;1;53-60

  • Transcriptomic profiling facilitates classification of response to influenza challenge.

    Davenport EE, Antrobus RD, Lillie PJ, Gilbert S and Knight JC

    Journal of molecular medicine (Berlin, Germany) 2015;93;1;105-14

  • A common haplotype of the TNF receptor 2 gene modulates endotoxin tolerance.

    Fairfax BP, Davenport EE, Makino S, Hill AV, Vannberg FO and Knight JC

    Journal of immunology (Baltimore, Md. : 1950) 2011;186;5;3058-65